Jehrod Brenneman
Research Subjects
Jehrod Brenneman has a total of 29 co-authors. Here are the top co-authors by number of shared publications:
- Andrew A. Wylie
KSQ Therapeutics, Lexington, Massachusetts
25 shared publications - Andrew Olaharski
KSQ Therapeutics, Lexington, Massachusetts. 1
25 shared publications - Anne E. Dodson
Department of Genetics, Blavatnik Institute at Harvard Medical School, Boston, USA
25 shared publications - Dipen Sangurdekar
KSQ Therapeutics, Inc
25 shared publications - Edmond Chipumuro
KSQ Therapeutics, Lexington, Massachusetts
25 shared publications - Elsa Krall
KSQ Therapeutics, Lexington, Massachusetts. 1
25 shared publications
Latest Publications
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S7 from The USP1 Inhibitor KSQ-4279 Overcomes PARP Inhibitor Resistance in Homologous Recombination–Deficient Tumors
Clonogenic assays in the presence of KSQ-4279 and olaparib in combination
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S7 from The USP1 Inhibitor KSQ-4279 Overcomes PARP Inhibitor Resistance in Homologous Recombination–Deficient Tumors
Clonogenic assays in the presence of KSQ-4279 and olaparib in combination
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S9 from The USP1 Inhibitor KSQ-4279 Overcomes PARP Inhibitor Resistance in Homologous Recombination–Deficient Tumors
Mouse body weight measurements following treatment with KSQ-4279 and olaparib
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S9 from The USP1 Inhibitor KSQ-4279 Overcomes PARP Inhibitor Resistance in Homologous Recombination–Deficient Tumors
Mouse body weight measurements following treatment with KSQ-4279 and olaparib
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table 1 from The USP1 Inhibitor KSQ-4279 Overcomes PARP Inhibitor Resistance in Homologous Recombination–Deficient Tumors
Cell line vendor and growth media
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 1 from The USP1 Inhibitor KSQ-4279 Overcomes PARP Inhibitor Resistance in Homologous Recombination–Deficient Tumors
Cell line vendor and growth media
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S2 from The USP1 Inhibitor KSQ-4279 Overcomes PARP Inhibitor Resistance in Homologous Recombination–Deficient Tumors
Enzyme kinetic studies of KSQ-4279
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S2 from The USP1 Inhibitor KSQ-4279 Overcomes PARP Inhibitor Resistance in Homologous Recombination–Deficient Tumors
Enzyme kinetic studies of KSQ-4279
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S3 from The USP1 Inhibitor KSQ-4279 Overcomes PARP Inhibitor Resistance in Homologous Recombination–Deficient Tumors
KSQ-4279 CryoEM data collection
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S3 from The USP1 Inhibitor KSQ-4279 Overcomes PARP Inhibitor Resistance in Homologous Recombination–Deficient Tumors
KSQ-4279 CryoEM data collection
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S8 from The USP1 Inhibitor KSQ-4279 Overcomes PARP Inhibitor Resistance in Homologous Recombination–Deficient Tumors
Combination studies using KSQ-4279 and PARP inhibitors
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S8 from The USP1 Inhibitor KSQ-4279 Overcomes PARP Inhibitor Resistance in Homologous Recombination–Deficient Tumors
Combination studies using KSQ-4279 and PARP inhibitors
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table 2 from The USP1 Inhibitor KSQ-4279 Overcomes PARP Inhibitor Resistance in Homologous Recombination–Deficient Tumors
List of antibodies used for immunoblotting
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 2 from The USP1 Inhibitor KSQ-4279 Overcomes PARP Inhibitor Resistance in Homologous Recombination–Deficient Tumors
List of antibodies used for immunoblotting
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S1 from The USP1 Inhibitor KSQ-4279 Overcomes PARP Inhibitor Resistance in Homologous Recombination–Deficient Tumors
USP1/UAF1 CRISPR dependency profiles
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S1 from The USP1 Inhibitor KSQ-4279 Overcomes PARP Inhibitor Resistance in Homologous Recombination–Deficient Tumors
USP1/UAF1 CRISPR dependency profiles
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table 3 from The USP1 Inhibitor KSQ-4279 Overcomes PARP Inhibitor Resistance in Homologous Recombination–Deficient Tumors
CRISPR dropout scores for USP1 and UAF1
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 3 from The USP1 Inhibitor KSQ-4279 Overcomes PARP Inhibitor Resistance in Homologous Recombination–Deficient Tumors
CRISPR dropout scores for USP1 and UAF1
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S4 from The USP1 Inhibitor KSQ-4279 Overcomes PARP Inhibitor Resistance in Homologous Recombination–Deficient Tumors
KSQ-4279 CryoEM workflow and resolution distribution
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S4 from The USP1 Inhibitor KSQ-4279 Overcomes PARP Inhibitor Resistance in Homologous Recombination–Deficient Tumors
KSQ-4279 CryoEM workflow and resolution distribution